Simulations Plus Inc (SLP)

Simulations Plus, Inc. is a NASDAQ-listed common stock company focused on healthcare technology. The company develops software and consulting services for drug discovery and development, with an emphasis on modeling, simulation, and prediction of molecular properties using artificial intelligence and machine learning tools. Its operations are organized into Software and Services segments. Key products include GastroPlus, which is used to model absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics, along with DDDPlus, MembranePlus, and a range of mechanistic modeling programs such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales. Simulations Plus also provides ADMET Predictor, MedChem Designer, and MonolixSuite, as well as clinical pharmacology consulting, data programming, technical writing, and early drug discovery support. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory organizations. It was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.